A-Skin secures patent for groundbreaking skin engineering therapy

WHF therapy can be directly applied on a wound to stimulate the natural human wound healing process.

A-Skin has secured an important patent for its groundbreaking Wound Healing Formulation (WHF) therapy. The worldwide market for this indication is estimated at $20.5 billion by 2020. Furthermore, A-Skin’s lead product Tiscover is ready to enter a clinical phase II trial after finalization of an ongoing financing round to raise €7,5 million.

WHF is a substance that can be directly applied on a wound to stimulate the wound healing. WHF consists of wound healing factors secreted by cultured immortalized human skin cells, with the potential to vitalize the natural human wound healing process. WHF substance can be applied directly on the wound bed in a gel, blister, bandage etc. The target population is everyone with a small simple skin wound that needs wound healing stimulation. WHF is classified as a Non-Cell Based Medicinal Product at the EMA.

Prof. dr. Rik J. Scheper, A-Skin’s CEO, comments: "Securing the IP of WHF means a very important milestone for our company, with now two ground breaking skin engineering products in our pipeline. Both WHF and Tiscover tap into a huge worldwide market for regenerative skin engineering medicine and non-healing chronic wound treatment. Some 50 million patients around the globe suffer from non-healing wounds following higher incidence of diabetes, ageing and growing immobilization. Therefore our solutions have a large societal impact by healing patients wounds, taking away the pain and giving back their self-esteem."